Danielle Antalffy
Stock Analyst at UBS
(3.35)
# 1,018
Out of 4,735 analysts
172
Total ratings
46.36%
Success rate
3.45%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXST RxSight | Initiates: Buy | $52 | $30.97 | +67.90% | 2 | Dec 6, 2024 | |
| GKOS Glaukos | Initiates: Buy | $182 | $159.34 | +14.22% | 1 | Dec 6, 2024 | |
| SGHT Sight Sciences | Initiates: Buy | $5.5 | $2.89 | +90.31% | 1 | Dec 6, 2024 | |
| SYK Stryker | Maintains: Neutral | $366 → $370 | $395.85 | -6.53% | 6 | Oct 30, 2024 | |
| ATRC AtriCure | Maintains: Buy | $35 → $40 | $39.63 | +0.93% | 12 | Oct 30, 2024 | |
| ABT Abbott Laboratories | Maintains: Buy | $143 → $146 | $116.79 | +25.01% | 11 | Oct 17, 2024 | |
| EW Edwards Lifesciences | Maintains: Neutral | $90 → $75 | $69.97 | +7.19% | 12 | Sep 10, 2024 | |
| MDT Medtronic | Upgrades: Neutral | $76 → $90 | $88.38 | +1.83% | 7 | Aug 15, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Sell | $112 → $107 | $110.52 | -3.18% | 4 | Aug 8, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Neutral | $6.5 → $7 | $9.27 | -24.49% | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $163 → $95 | $86.32 | +10.06% | 8 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $90 | $100.91 | -10.81% | 11 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $26 | $16.96 | +53.30% | 3 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $47.99 | +56.28% | 1 | Jan 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $180 | $148.15 | +21.50% | 4 | Dec 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $405 → $322 | $185.09 | +73.97% | 5 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $3.91 | -42.46% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $43 | $31.48 | +36.59% | 5 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $278 | $604.12 | -53.98% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $45 | $35.30 | +27.48% | 14 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $280 | $276.08 | +1.42% | 12 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $55 | $0.81 | +6,716.21% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $18.97 | -26.20% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $94.05 | +6.33% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $13.06 | -8.12% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $30 | $69.75 | -56.99% | 3 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $59.56 | -24.45% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $85 | $4.68 | +1,716.24% | 10 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $95 | $79.50 | +19.50% | 6 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $240.37 | +14.41% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $3.53 | +466.57% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $11.19 | +275.34% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $3 | $0.91 | +231.35% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $1.04 | +1,342.31% | 1 | Sep 1, 2020 |
RxSight
Dec 6, 2024
Initiates: Buy
Price Target: $52
Current: $30.97
Upside: +67.90%
Glaukos
Dec 6, 2024
Initiates: Buy
Price Target: $182
Current: $159.34
Upside: +14.22%
Sight Sciences
Dec 6, 2024
Initiates: Buy
Price Target: $5.5
Current: $2.89
Upside: +90.31%
Stryker
Oct 30, 2024
Maintains: Neutral
Price Target: $366 → $370
Current: $395.85
Upside: -6.53%
AtriCure
Oct 30, 2024
Maintains: Buy
Price Target: $35 → $40
Current: $39.63
Upside: +0.93%
Abbott Laboratories
Oct 17, 2024
Maintains: Buy
Price Target: $143 → $146
Current: $116.79
Upside: +25.01%
Edwards Lifesciences
Sep 10, 2024
Maintains: Neutral
Price Target: $90 → $75
Current: $69.97
Upside: +7.19%
Medtronic
Aug 15, 2024
Upgrades: Neutral
Price Target: $76 → $90
Current: $88.38
Upside: +1.83%
Zimmer Biomet Holdings
Aug 8, 2024
Maintains: Sell
Price Target: $112 → $107
Current: $110.52
Upside: -3.18%
Treace Medical Concepts
Aug 7, 2024
Maintains: Neutral
Price Target: $6.5 → $7
Current: $9.27
Upside: -24.49%
Jul 26, 2024
Maintains: Buy
Price Target: $163 → $95
Current: $86.32
Upside: +10.06%
Apr 25, 2024
Maintains: Buy
Price Target: $74 → $90
Current: $100.91
Upside: -10.81%
Feb 14, 2024
Maintains: Neutral
Price Target: $24 → $26
Current: $16.96
Upside: +53.30%
Jan 22, 2024
Initiates: Buy
Price Target: $75
Current: $47.99
Upside: +56.28%
Dec 1, 2023
Upgrades: Buy
Price Target: $180
Current: $148.15
Upside: +21.50%
Sep 6, 2023
Maintains: Buy
Price Target: $405 → $322
Current: $185.09
Upside: +73.97%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $3.91
Upside: -42.46%
Mar 29, 2023
Initiates: Neutral
Price Target: $43
Current: $31.48
Upside: +36.59%
Mar 29, 2023
Initiates: Neutral
Price Target: $278
Current: $604.12
Upside: -53.98%
Mar 29, 2023
Initiates: Neutral
Price Target: $45
Current: $35.30
Upside: +27.48%
May 6, 2022
Maintains: Outperform
Price Target: $300 → $280
Current: $276.08
Upside: +1.42%
May 5, 2022
Maintains: Outperform
Price Target: $65 → $55
Current: $0.81
Upside: +6,716.21%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $18.97
Upside: -26.20%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $94.05
Upside: +6.33%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $13.06
Upside: -8.12%
Mar 9, 2022
Maintains: Outperform
Price Target: $25 → $30
Current: $69.75
Upside: -56.99%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $59.56
Upside: -24.45%
Feb 24, 2022
Maintains: Outperform
Price Target: $105 → $85
Current: $4.68
Upside: +1,716.24%
Feb 24, 2022
Maintains: Outperform
Price Target: $85 → $95
Current: $79.50
Upside: +19.50%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $240.37
Upside: +14.41%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $3.53
Upside: +466.57%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $11.19
Upside: +275.34%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $3
Current: $0.91
Upside: +231.35%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $1.04
Upside: +1,342.31%